BioNTech (BNTX) Competitors

$87.79 -1.06 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$88.26 +0.47 (+0.53%)

As of 07:51 PM Eastern

BNTX vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy BioNTech stock or one of its competitors? MarketBeat compares BioNTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNTech include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does BioNTech compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Takeda Pharmaceutical has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to BioNTech's net margin of -44.39%. Takeda Pharmaceutical's return on equity of 11.07% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
BioNTech	-44.39%	-5.30%	-4.62%

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Takeda Pharmaceutical had 10 more articles in the media than BioNTech. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 6 mentions for BioNTech. Takeda Pharmaceutical's average media sentiment score of 0.06 beat BioNTech's score of -0.10 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Takeda Pharmaceutical has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.53
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A

BioNTech has a consensus price target of $130.60, suggesting a potential upside of 48.76%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Summary

Takeda Pharmaceutical beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does BioNTech compare to argenex?

argenex (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

argenex currently has a consensus price target of $1,017.78, indicating a potential upside of 27.58%. BioNTech has a consensus price target of $130.60, indicating a potential upside of 48.76%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

argenex has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 33.28% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
BioNTech	-44.39%	-5.30%	-4.62%

In the previous week, BioNTech had 1 more articles in the media than argenex. MarketBeat recorded 6 mentions for BioNTech and 5 mentions for argenex. argenex's average media sentiment score of 0.72 beat BioNTech's score of -0.10 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.62	$1.29B	$22.46	35.52
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A

60.3% of argenex shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

argenex beats BioNTech on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 6 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 0.63 beat BioNTech's score of -0.10 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	9 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BioNTech's net margin of -44.39%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BioNTech	-44.39%	-5.30%	-4.62%

Teva Pharmaceutical Industries has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.65
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, suggesting a potential upside of 22.44%. BioNTech has a consensus target price of $130.60, suggesting a potential upside of 48.76%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to BeOne Medicines?

BioNTech (NASDAQ:BNTX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

BeOne Medicines has a net margin of 8.94% compared to BioNTech's net margin of -44.39%. BeOne Medicines' return on equity of 12.06% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
BeOne Medicines	8.94%	12.06%	6.69%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BeOne Medicines has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A
BeOne Medicines	$5.34B	6.10	$286.93M	$4.47	66.45

BioNTech currently has a consensus target price of $130.60, indicating a potential upside of 48.76%. BeOne Medicines has a consensus target price of $389.15, indicating a potential upside of 31.02%. Given BioNTech's higher probable upside, research analysts clearly believe BioNTech is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, BeOne Medicines had 2 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for BeOne Medicines and 6 mentions for BioNTech. BeOne Medicines' average media sentiment score of 0.59 beat BioNTech's score of -0.10 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats BioNTech on 11 of the 16 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

BioNTech presently has a consensus price target of $130.60, indicating a potential upside of 48.76%. Revolution Medicines has a consensus price target of $108.88, indicating a potential downside of 26.09%. Given BioNTech's higher possible upside, research analysts clearly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	3.05

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.84	-$1.29B	-$5.88	N/A
Revolution Medicines	$11.58M	2,704.32	-$1.13B	-$7.07	N/A

In the previous week, BioNTech and BioNTech both had 6 articles in the media. Revolution Medicines' average media sentiment score of 0.53 beat BioNTech's score of -0.10 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 8.2% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Revolution Medicines beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.20B	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-14.93	18.70	20.58	25.11
Price / Sales	6.84	278.20	577.42	91.32
Price / Cash	67.07	55.27	27.48	37.30
Price / Book	0.91	6.57	9.68	6.60
Net Income	-$1.29B	$24.30M	$3.55B	$335.71M
7 Day Performance	-6.27%	-3.56%	-2.07%	-2.03%
1 Month Performance	-14.70%	-7.86%	-3.90%	-1.90%
1 Year Performance	-10.24%	51.80%	29.39%	27.36%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	3.9049 of 5 stars	$87.79 -1.2%	$130.60 +48.8%	-4.2%	$22.20B	$3.25B	N/A	7,807
TAK Takeda Pharmaceutical	2.0361 of 5 stars	$16.34 -0.8%	N/A	+17.5%	$52.38B	$30.09B	68.07	47,455	Analyst Downgrade
ARGX argenex	4.6501 of 5 stars	$813.28 +4.0%	$1,017.78 +25.1%	+37.2%	$48.64B	$4.25B	36.21	1,863
TEVA Teva Pharmaceutical Industries	4.5311 of 5 stars	$35.91 +0.5%	$41.78 +16.3%	+101.1%	$41.08B	$17.26B	27.00	33,950	Trending News Insider Trade
ONC BeOne Medicines	4.2669 of 5 stars	$310.75 -0.4%	$391.00 +25.8%	+28.3%	$34.25B	$5.74B	69.52	12,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BioNTech compare to Takeda Pharmaceutical?

Summary

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Summary

How does BioNTech compare to BeOne Medicines?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BioNTech compare to Takeda Pharmaceutical?

Which has more risk and volatility, TAK or BNTX?

Is TAK or BNTX more profitable?

Do institutionals & insiders hold more shares of TAK or BNTX?

Does the media prefer TAK or BNTX?

Which has better valuation and earnings, TAK or BNTX?

Do analysts prefer TAK or BNTX?

Summary

How does BioNTech compare to argenex?

Do analysts prefer ARGX or BNTX?

Which has more volatility & risk, ARGX or BNTX?

Is ARGX or BNTX more profitable?

Does the media favor ARGX or BNTX?

Which has preferable valuation & earnings, ARGX or BNTX?

Do insiders and institutionals hold more shares of ARGX or BNTX?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Does the media prefer TEVA or BNTX?

Is TEVA or BNTX more profitable?

Which has stronger earnings & valuation, TEVA or BNTX?

Do analysts recommend TEVA or BNTX?

Do insiders & institutionals hold more shares of TEVA or BNTX?

Which has more risk & volatility, TEVA or BNTX?

Summary

How does BioNTech compare to BeOne Medicines?

Which has more volatility & risk, BNTX or ONC?

Is BNTX or ONC more profitable?

Do insiders and institutionals believe in BNTX or ONC?

Which has higher earnings and valuation, BNTX or ONC?

Do analysts recommend BNTX or ONC?

Does the media refer more to BNTX or ONC?

Summary

How does BioNTech compare to Revolution Medicines?

Do analysts recommend BNTX or RVMD?

Which has stronger earnings & valuation, BNTX or RVMD?

Does the media refer more to BNTX or RVMD?

Do institutionals & insiders hold more shares of BNTX or RVMD?

Which has more volatility and risk, BNTX or RVMD?

Is BNTX or RVMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools